ArticleScientific reports2025
Melanoma GPA as a novel prognostic scoring model based on initial brain metastasis velocity.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Upon initial presentation, initial brain metastasis velocity (iBMV) is a prognostic factor for patients with brain metastases (BMs). Based on this metric, this study validated the predictive value of iBMV and introduced a Graded Prognostic Assessment (GPA)-derived scale known as melanoma-GPA. We conducted a retrospective cohort study and enrolled patients diagnosed with malignant melanoma brain metastases (MBMs) between December 2010 and February 2023. We performed univariate and multivariate Cox regression analyses to identify prognostic factors affecting overall survival (OS). A novel prognostic scoring model was derived using these factors, then melanoma-GPA and GPA predictive capabilities were assessed and compared. We enrolled 111 patients with a median OS and iBMV of 11.80 months and 2.27, respectively. The Kaplan-Meier curves showed that patients with iBMV ≤ 2.27 have better prognostic performance (P < 0.001). Multivariate analysis showed that iBMV (P = 0.035), Karnofsky Performance Status (P < 0.001), serum lactate dehydrogenase (P = 0.028), serum albumin (P = 0.041), and the systemic immune-inflammation index (P = 0.042) were independent predictors of OS. Subsequently, we established the melanoma-GPA. After risk stratification, the low-risk group had significantly longer survival than the high-risk group (17.7 vs. 7.9 months). In addition, over 3 years, the melanoma-GPA area under the curve (AUC) values were superior to GPA AUC values, indicating that melanoma-GPA has greater predictive accuracy. This study has shown that iBMV is a prognostic indicator in MBMs. Based on this factor, we established the Melanoma-GPA to comprehensively and objectively assess the prognosis of MBMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.